Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07618520 · ClinicalTrials.gov registry record · NA
Expanding Genetic Access for Prostate Cancer Survivors
A NA study, sponsored by Georgetown University.
- Not yet
- Registry status
- NA
- Development phase
- 500
- Enrollment target
NCT07618520 is a NA study that has not yet begun recruiting, run by Georgetown University. The registered enrollment target is 500 participants.
The verdict
NCT07618520, a NA study, has not yet begun recruiting, sponsored by Georgetown University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
Study Summary
The goal of this study is to increase genetic education and genetic testing for hereditary cancer risk among prostate cancer survivors. The study will: Test the effectiveness of a digital guide (DG+) vs. print guide (Print+) vs. enhanced usual care (EUC) on engagement in genetic education and uptake of genetic testing. Evaluate the impact of the DG+ vs. Print+ vs. EUC on the process that participants use to make decisions and evaluate effects on well-being (also called psychosocial outcomes). Explore the ways (methods) that influence how participants experience the intervention. The main questions this study aims to answer are: which group - the digital guide (DG+) group, print (Print+) group or the EUC group - is more likely to request genetic testing and which group is more likely to get (engage with) genetic education. Participants will be randomly assigned to either the digital guide (DG+) group, the print guide (Print+) group or EUC group. Each group will receive genetic education and have an opportunity to request genetic testing. Researchers will compare the three groups to determine which is most most likely to complete genetic testing (GT) and which group engages more with genetic education.
Interventions
- BEHAVIORAL Enhanced Usual Care
- BEHAVIORAL Print Genetic Education Guide
- BEHAVIORAL Digital Guide Genetic Education Guide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2030-07-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07618520
The ClinicalTrials.gov registry entry for NCT07618520 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Enhanced Usual Care is the first listed.
NCT07618520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07618520 about?
NCT07618520 is a clinical study titled "Expanding Genetic Access for Prostate Cancer Survivors". The goal of this study is to increase genetic education and genetic testing for hereditary cancer risk among prostate cancer survivors. The study will: Test the effectiveness of a digital guide (DG+) vs. print guide (Print+) vs. enhanced usual care (EUC) on engagement in genetic education and uptak...
What is the current status of trial NCT07618520?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2026-08-01. Estimated completion is 2030-07-31.
What interventions are being tested in trial NCT07618520?
The interventions under investigation include: Enhanced Usual Care (BEHAVIORAL), Print Genetic Education Guide (BEHAVIORAL), Digital Guide Genetic Education Guide (BEHAVIORAL).
Who is sponsoring clinical trial NCT07618520?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.